APA (7th ed.) Citation

JL, K., JS, L., HJ, G., J, R., J, G., H, R., . . . Smit, E. F. (2012). VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib. British Journal of Cancer, 107(11), 1820. https://doi.org/10.1038/bjc.2012.470

Chicago Style (17th ed.) Citation

JL, Kuiper, et al. "VeriStrat(®) Has Prognostic Value in Advanced Stage NSCLC Patients Treated with Erlotinib and Sorafenib." British Journal of Cancer 107, no. 11 (2012): 1820. https://doi.org/10.1038/bjc.2012.470.

MLA (9th ed.) Citation

JL, Kuiper, et al. "VeriStrat(®) Has Prognostic Value in Advanced Stage NSCLC Patients Treated with Erlotinib and Sorafenib." British Journal of Cancer, vol. 107, no. 11, 2012, p. 1820, https://doi.org/10.1038/bjc.2012.470.